Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Journal of the American Academy of Dermatology|June 9, 2016
Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)Eric L Simpson, Abhijit Gadkari, Margitta Worm, et al.
The World Allergy Organization Journal|November 28, 2022
Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticariaMartin Metz, Jonathan A Bernstein, Ana M Giménez-Arnau, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 19, 2020
Biologic and maintenance systemic corticosteroid therapy among US subspecialist-treated patients with severe asthmaWendy C Moore, Reynold A Panettieri, Jennifer Trevor, et al.
Dermatology and Therapy|July 22, 2025
Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical TrialsAndrew F Alexis, Leon Kircik, Raj Chovatiya, et al.
Dermatology and Therapy|October 27, 2022
Predicting Clinical Remission of Chronic Urticaria Using Random Survival Forests: Machine Learning Applied to Real-World DataIrina Pivneva, Maria-Magdalena Balp, Yvonne Geissbühler, et al.
The Journal of Allergy and Clinical Immunology|August 17, 2021
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study resultsJonathan I Silverberg, Marjolein de Bruin-Weller, Thomas Bieber, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 15, 2024
Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 PopulationJonathan Corren, Stanley J Szefler, Ellen Sher, et al.
Lancet (London, England)|May 23, 2021
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trialKristian Reich, Henrique D Teixeira, Marjolein de Bruin-Weller, et al.
Lancet (London, England)|July 25, 2022
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trialKristian Reich, Jacob P Thyssen, Andrew Blauvelt, et al.
The Journal of Allergy and Clinical Immunology|April 19, 2021
Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trialSteven G Kelsen, Ioana O Agache, Weily Soong, et al.
Pageof 6